In pulmonary arterial hypertension ( PAH ), combination therapy is an important treatment strategy.
Although randomized controlled trial data are available to support the combination of two therapies, data regarding triple combination therapy are few.
The phase III GRIPHON trial enrolled 1156 patients with pulmonary arterial hypertension, including 376 receiving background double combination therapy.
Researchers have evaluated the efficacy and safety of Selexipag ( Uptravi ) as a third agent in these patients and further analyzed this subgroup according to symptom burden at baseline as indicated by World Health Organization ( WHO ) functional class ( FC ).
Of 376 patients receiving background endothelin receptor antagonist ( ERA ) and phosphodiesterase-5 inhibitor ( PDE-5i ) therapy, 115 had WHO FC II symptoms and 255 had WHO FC III symptoms at baseline.
The impact on the primary endpoint of adding Selexipag versus placebo to double combination therapy was consistent with the effect in the overall population ( hazard ratio, HR=0.63; 95% CI 0.44-0.90 ) as well as in patients with WHO FC II and III symptoms.
Compared with the overall population, discontinuations due to an adverse event were higher when Selexipag was added to background double combination therapy; no safety concerns were identified.
In conclusion, the addition of Selexipag to background double combination therapy with an ERA and PDE-5i provides an incremental benefit similar to that seen in the overall population, including in patients with WHO FC II or III symptoms at baseline. ( Xagena )
Coghlan JG et al, Am J Cardiovasc Drugs 2018; 18: 37-47